Reduction of alcohol consumption

Active Ingredient: Nalmefene

Indication for Nalmefene

Population group: only adults (18 years old or older)

Nalmefene is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification.

Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.

Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.

For this indication, competent medicine agencies globally authorize below treatments:

18.06 mg once

Route of admnistration

Oral

Defined daily dose

18.06 - 18.06 mg

Dosage regimen

From 18.06 To 18.06 mg once every day

Detailed description

At an initial visit, the patient’s clinical status, alcohol dependence, and level of alcohol consumption (based on patient reporting) should be evaluated. Thereafter, the patient should be asked to record his or her alcohol consumption for approximately two weeks.

At the next visit, nalmefene may be initiated in patients who continued to have a high DRL over this two-week period, in conjunction with psychosocial intervention focused on treatment adherence and reducing alcohol consumption.

Nalmefene is to be taken as-needed: On each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.

The maximum dose of nalmefene is one tablet per day.

During pivotal trials the greatest improvement was observed within the first 4 weeks. The patient’s response to treatment and the need for continued pharmacotherapy should be evaluated on a regular (for example, monthly) basis. The physician should continue to assess the patient’s progress in reducing alcohol consumption, overall functioning, treatment adherence, and any potential side effects. Clinical data for the use of nalmefene under randomised controlled conditions are available for a period of 6 to 12 months. Caution is advised if nalmefene is prescribed for more than 1 year.

Dosage considerations

Nalmefene can be taken with or without food.

Active ingredient

Nalmefene

Nalmefene is an opioid system modulator with a distinct ÎŒ, ÎŽ, and Îș receptor profile. Nalmefene is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence, without physical withdrawal symptoms and who do not require immediate detoxification.

Read more about Nalmefene

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.